Korea Investment CORP Purchases 159,899 Shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA)

Korea Investment CORP grew its holdings in shares of Teva Pharmaceutical Industries Limited (NYSE:TEVA) by 72.0% in the fourth quarter, Holdings Channel.com reports. The firm owned 381,955 shares of the company’s stock after buying an additional 159,899 shares during the period. Korea Investment CORP’s holdings in Teva Pharmaceutical Industries were worth $8,418,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently modified their holdings of TEVA. Wilmington Savings Fund Society FSB bought a new stake in shares of Teva Pharmaceutical Industries during the 3rd quarter valued at $50,000. Ameliora Wealth Management Ltd. bought a new stake in shares of Teva Pharmaceutical Industries during the fourth quarter valued at about $66,000. IFP Advisors Inc lifted its holdings in shares of Teva Pharmaceutical Industries by 96.1% in the fourth quarter. IFP Advisors Inc now owns 3,999 shares of the company’s stock worth $88,000 after buying an additional 1,960 shares in the last quarter. C2P Capital Advisory Group LLC d.b.a. Prosperity Capital Advisors bought a new position in shares of Teva Pharmaceutical Industries in the fourth quarter valued at approximately $104,000. Finally, Assetmark Inc. grew its stake in Teva Pharmaceutical Industries by 1,370.3% during the fourth quarter. Assetmark Inc. now owns 5,205 shares of the company’s stock valued at $115,000 after acquiring an additional 4,851 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company’s stock.

Teva Pharmaceutical Industries Trading Up 2.0 %

TEVA stock opened at $15.39 on Tuesday. The company has a market capitalization of $17.44 billion, a PE ratio of -10.61, a price-to-earnings-growth ratio of 1.44 and a beta of 0.82. The company has a debt-to-equity ratio of 2.97, a quick ratio of 0.75 and a current ratio of 0.98. Teva Pharmaceutical Industries Limited has a one year low of $12.51 and a one year high of $22.80. The company’s 50 day moving average price is $17.08 and its two-hundred day moving average price is $18.11.

Teva Pharmaceutical Industries (NYSE:TEVA) last posted its quarterly earnings results on Wednesday, January 29th. The company reported $0.70 earnings per share for the quarter, topping the consensus estimate of $0.69 by $0.01. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. As a group, analysts predict that Teva Pharmaceutical Industries Limited will post 2.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have commented on TEVA. StockNews.com downgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “hold” rating in a report on Thursday, March 27th. Bank of America reduced their target price on Teva Pharmaceutical Industries from $23.00 to $20.00 and set a “buy” rating for the company in a research report on Thursday, March 6th. Piper Sandler raised their price target on Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an “overweight” rating in a report on Friday, January 17th. Barclays cut their price objective on Teva Pharmaceutical Industries from $28.00 to $26.00 and set an “overweight” rating for the company in a report on Thursday, January 30th. Finally, UBS Group dropped their target price on shares of Teva Pharmaceutical Industries from $30.00 to $27.00 and set a “buy” rating for the company in a research report on Thursday, January 30th. Two equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $23.43.

Teva Pharmaceutical Industries Company Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.